Bank of New York Mellon’s Aratana Therapeutics, Inc. PETX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-169,284
Closed -$874K 4306
2019
Q2
$874K Buy
169,284
+2,829
+2% +$12.7K ﹤0.01% 3310
2019
Q1
$599K Buy
166,455
+2,273
+1% +$9.85K ﹤0.01% 3465
2018
Q4
$1.01M Buy
164,182
+16,270
+11% +$99.3K ﹤0.01% 3096
2018
Q3
$864K Sell
147,912
-705
-0.5% -$3.52K ﹤0.01% 3359
2018
Q2
$632K Buy
148,617
+3,180
+2% +$16K ﹤0.01% 3511
2018
Q1
$641K Buy
145,437
+879
+0.6% +$3.92K ﹤0.01% 3456
2017
Q4
$760K Buy
144,558
+5,496
+4% +$33.6K ﹤0.01% 3405
2017
Q3
$853K Buy
139,062
+1,960
+1% +$12.4K ﹤0.01% 3313
2017
Q2
$992K Buy
137,102
+11,229
+9% +$69.1K ﹤0.01% 3258
2017
Q1
$667K Sell
125,873
-3,786
-3% -$25.6K ﹤0.01% 3439
2016
Q4
$931K Sell
129,659
-7,642
-6% -$61.8K ﹤0.01% 3298
2016
Q3
$1.28M Buy
137,301
+437
+0.3% +$3.63K ﹤0.01% 3040
2016
Q2
$866K Buy
136,864
+19,590
+17% +$126K ﹤0.01% 3242
2016
Q1
$647K Sell
117,274
-12,818
-10% -$48.2K ﹤0.01% 3311
2015
Q4
$726K Sell
130,092
-24,525
-16% -$162K ﹤0.01% 3355
2015
Q3
$1.31M Sell
154,617
-9,976
-6% -$169K ﹤0.01% 3014
2015
Q2
$2.49M Sell
164,593
-33,899
-17% -$489K ﹤0.01% 2766
2015
Q1
$3.18M Buy
198,492
+2,482
+1% +$44.2K ﹤0.01% 2570
2014
Q4
$3.49M Buy
196,010
+63,421
+48% +$790K ﹤0.01% 2506
2014
Q3
$1.33M Sell
132,589
-2,806
-2% -$34K ﹤0.01% 3130
2014
Q2
$2.11M Buy
135,395
+53,566
+65% +$759K ﹤0.01% 2876
2014
Q1
$1.52M Buy
81,829
+50,995
+165% +$1.02M ﹤0.01% 3060
2013
Q4
$589K Buy
30,834
+17,167
+126% +$349K ﹤0.01% 3519
2013
Q3
$224K Buy
+13,667
New +$144K ﹤0.01% 3766

Other funds holding PETX

Bank of New York Mellon's PETX Position: Q3 2019 in Review

Bank of New York Mellon sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 169,284 shares — an estimated $874K sold.

Bank of New York Mellon first reported a position in PETX in Q3 2013 and held it in 24 quarters. The position peaked at $3.49M in Q4 2014. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

  • Bank of New York Mellon reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Bank of New York Mellon sold 169,284 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $874K.
  • Bank of New York Mellon first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and held it in 24 quarters.
  • Bank of New York Mellon's Aratana Therapeutics, Inc. position peaked at $3.49M in Q4 2014.
  • 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Bank of New York Mellon's 13F filing for Q3 2019, filed 7 Nov 2019.